|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Patterned maeroarray plates in comparison of bacterial adhesion inhibition of tantalum, titanium, and chromium compared with diamond-like carbon显示文摘 | LEVON J MYLLYMAA K KOURI V P | 2010 | J Biomed Mater Res A2010，92，4： | 1 |
| 2 | 显示文摘 | Levon K | 1998 | Polym Prepri1998，39，1： | 1 |
| 3 | 查看详情显示文摘 | Wang Y T Zhou Y X Sokolov J Rigas B Levon K Rafailovich M | | 0，，： | 1 |
| 4 | 查看详情显示文摘 | Wang Y T Zhang Z Q Jain V Yi J J Mueller S Sokolov J Liu Z X Levon K Rigas B Rafailovich M H | | 0，，： | 1 |
| 5 | Prediction of effective stiffness in,laminates due to transverse cracking显示文摘 | MINNETYAN LEVON | 2007 | Journal of Com-posite Materials2007，41，1： | 1 |
| 6 | 显示文摘 | K Levon K H Ho W Y Zhang | 1995 | Polymer1995，36，14： | 1 |
| 7 | Divergent roles of NF-κB and Egr-1 in flow-dependent restenosis after angioplasty and stenting显示文摘 | Melanie M Levon M Ward MR | 2010 | Atherosclerosis2010，214，1： | 1 |
| 8 | Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study显示文摘BACKGROUND Biologic therapy resulted in a significant positive impact on the management of inflammatory bowel disease(IBD) however data on the efficacy and side effects of these therapies in the elderly is scant.AIM To evaluate retrospectively the drug sustainability, effectiveness, and safety of the biologic therapies in the elderly IBD population.METHODS Consecutive elderly(≥ 60 years old) IBD patients, treated with biologics [infliximab(IFX), adalimumab(ADAL), vedolizumab(VDZ), ustekinumab(UST)] followed at the McGill University Inflammatory Bowel Diseases Center were included between January 2000 and 2020.Efficacy was measured by clinical scores at 3, 6-9 and 12-18 mo after initiation of the biologic therapy. Patients completing induction therapy were included. Adverse events(AEs) or serious AE were collected during and within three months of stopping of the biologic therapy.RESULTS We identified a total of 147 elderly patients with IBD treated with biologicals during the study period, including 109 with Crohn’s disease and 38 with ulcerative colitis. Patients received the following biologicals: IFX(28.5%), ADAL(38.7%), VDZ(15.6%), UST(17%). The mean duration of biologic treatment was 157.5(SD = 148) wk. Parallel steroid therapy was given in 34% at baseline,19% at 3 mo, 16.3% at 6-9 mo and 6.5% at 12-18 mo. The remission rates at 3, 6-9 and 12-18 mo were not significantly different among biological therapies. Kaplan-Meyer analysis did not show statistical difference for drug sustainability(P = 0.195), time to adverse event(P = 0.158) or infection rates(P = 0.973) between the four biologics studied. The most common AEs that led to drug discontinuation were loss of response, infusion/injection reaction and infection.CONCLUSION Current biologics were not different regarding drug sustainability, effectiveness, and safety in the elderly IBD population. Therefore, we are not able to suggest a preferred sequencing order among biologicals. | Gustavo Drugg Hahn Jean-Frederic LeBlanc Petra Anna Golovics Panu Wetwittayakhlang Abdulrahman Qatomah Anna Wang Levon Boodaghians Jeremy Liu Chen Kiow Maryam Al Ali Gary Wild Waqqas Afif Alain Bitton Peter Laszlo Lakatos Talat Bessissow | 2022 | World Journal of Gastroenterology2022，28，33： | 1 |
| 9 | Nanocomposites at elevated temperatures: Migration and structural changes 显示文摘 | Lewin M Pearce E M Levon K | 2006 | Polym Adv Technol2006，17，4： | 1 |
| 10 | Angiotensin II–Inducible Smooth Muscle Cell Apoptosis Involves the Angiotensin II Type 2 Receptor, GATA-6 Activation, and FasL-Fas Engagement显示文摘 | Nicole Y. Tan Jian-Mei Li Roland Stocker Levon M. Khachigian | 2009 | Circulation Research2009，，5： | 1 |
| 11 | Nucleating agents in polypropylene 显示文摘 | NAGARAJAN K LEVON K MYERSON A S | 2000 | J Therm Anal Cal2000，59，： | 1 |
| 12 | Nonequilibrium liquid-liquid phase separation in crystallizable polymer solutions 显示文摘 | LEE H K MYERSON A S LEVON K | 1992 | Macromolecules1992，25，： | 1 |
| 13 | Early Growth Response-1 in Cardiovascular Pathobiology显示文摘 | Levon M. Khachigian | 2006 | Circulation Research2006，，2： | 1 |
| 14 | Defec/damage tol- erance of pressured fiber composite shells显示文摘 | Christos C Chamis Levon Minnetyan | 2001 | Composite Structure2001，51，： | 1 |
| 15 | Canonical and noncanonical Wnt pathway: A comparison among normal ovary,benign ovarian tumor and ovarian cancer显示文摘 | Levon Badiglian Filho Celina Oshima Flávio De Oliveira Lima Henrique De Oliveira Costa Robério De Sousa Dami?o Thiago Gomes Wagner Gon?alves | 2009 | Oncology Reports2009，，2： | 1 |
| 16 | 显示文摘 | Laakso Levon K | 1994 | Solid State Comm1994，92，： | 1 |
| 17 | Nonequilibrium Liquid- liquid phase separation in crystallizable polymer solutions显示文摘 | Lee H K Myerson A S Levon K | 1992 | Macromolecules1992，25，： | 1 |
| 18 | 转录调节因子Ets-1在大鼠血管平滑肌细胞增殖与凋亡中的作用显示文摘目的:研究转录调节因子Ets-1对大鼠血管平滑肌细胞增殖与凋亡的影响及其可能的机制。方法:用定量细胞DNA片段的方法观察大鼠血管平滑肌细胞增殖与凋亡。用W estern印迹法检测磷酸化视网膜母细胞瘤(RB-P)蛋白表达。结果:Ets-1抑制大鼠血管平滑肌细胞凋亡。反义P21WAF1/CIP1能够阻断Ets-1的抗凋亡作用,并抑制Ets-1诱导的平滑肌细胞增殖。Ets-1能够上调RB-P蛋白表达,反义P21WAF1/CIP1可以阻断Ets-1诱导的RB-P蛋白表达。结论:在大鼠血管平滑肌细胞中,Ets-1通过P21WAF1/CIP1旁路发挥抑制凋亡和促进增殖作用。 | 张翠丽 富路 Levon M.Khachigian | 2006 | 中国病理生理杂志2006，22，10： | 1 |
| 19 | M1-transitions and the mutual orientation of the unpaired nucleons in odd-odd nuclei显示文摘 | LEVON A I de BOER J PASTERNAK A A | 1992 | Zeitschrift Für Physik A1992，343，2： | 1 |
| 20 | Entry costs and cross-country differences in productivity and output显示文摘 | Levon Barseghyan | 2008 | Journal of Economic Growth2008，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员